Table 3.
Prevalence of CYP genotypes by group and sex.
| Full Sample (N=54) | Males (n=22) | Females (n=32) | ||||
|---|---|---|---|---|---|---|
| CYP3A4 | CUD | Control SUD | CUD | Control SUD | CUD | Control SUD |
| *1/*1 | 89.47% (34) | 100% (16) | 100% (13) | 100% (9) | 84.00% (21) | 100% (7) |
| *1/*18 | 2.63% (1) | 0 | 0 | 0 | 4.00% (1) | 0 |
| *1/*22 | 7.89% (3) | 0 | 0 | 0 | 12.00% (3) | 0 |
| CYP2C9 | ||||||
| *1/*1 | 71.05% (27) | 75% (12) | 84.62% (11) | 55.56% (5) | 64.00% (16) | 100% (7) |
| *1/*2 | 23.68% (9) | 12.50% (2) | 7.69% (1) | 22.22% (2) | 32.00% (8) | 0 |
| *2/*2 | 0 | 6.25% (1) | 0 | 11.11% (1) | 0 | 0 |
| *3/*1 | 5.26% (2) | 0 | 7.69% (1) | 0 | 4.00% (1) | 0 |
| *3/*2 | 0 | 6.25% (1) | 0 | 11.11% (1) | 0 | 0 |
Note: CUD = cannabis use disorder, Control SUD = control group with a non-CUD substance use disorder. For each gene assessed, proportions sum to 100%.